...Genmab A/S plucked a bundle of cancer targets from the remains of former proteomics company Europroteome AG...
...Genmab (CSE:GEN, Copenhagen, Denmark) obtained the rights to ZP3A and 15 other undisclosed targets from Europroteome's...
...or royalties on products that result (see BioCentury, May 23, 2005). "ZP3 is the first Europroteome...

...dependent cancers of epithelial cell origin, such as gastrointestinal cancers, from the insolvency administrator of Europroteome...
...milestone or royalty obligations. Europroteome filed for insolvency last August (see BioCentury, Aug. 23, 2004). Europroteome AG...

...dependent cancers of epithelial cell origin, such as gastrointestinal cancers, from the insolvency administrator of Europroteome...
...colon carcinomas. The purchase price was not disclosed. GEN has no milestone or royalty obligations. Europroteome...

...it is in negotiations with potential buyers to sell all or parts of the company. Europroteome AG...

...targeting membrane proteins for cancer, has filed for insolvency. According to CFO Walter von Horstig, Europroteome...
...develop in vitro breast cancer diagnostics that run on ABT's automated instruments. Also in July, Europroteome...

...instruments (see BioCentury, March 8). The expansion triggered and undisclosed milestone from ABT to Europroteome. Europroteome AG...

...companies partnered to develop in vitro breast cancer diagnostics that run on ABT's automated instruments. Europroteome...
...samples. Identified markers will be combined with ABT's panel of cancer markers for diagnostic development. Europroteome...
...milestone payments, and ABT has an option to license resulting discoveries in exchange for royalties. Europroteome AG...

...companies partnered to develop in vitro breast cancer diagnostics that run on ABT's automated instruments. Europroteome...
...samples. Identified markers will be combined with ABT's panel of cancer markers for diagnostic development. Europroteome...

...Disease Control validation technology in animal tumor models to validate one of Europroteome's cancer targets. Europroteome AG...

...Intradigm (Rockville, Md.) and Europroteome (Hennigsdorf, Germany) partnered to validate cancer targets using siRNA delivery in...
...use its siRNA-based Disease Control validation technology in animal models of cancer for one of Europroteome's...